MedTrace Logo

Hydroxyurea in the Treatment of Sickle Cell Disease

NCT02709681 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 628

Last updated 2017-10-06

No results posted yet for this study

Summary

This is a retrospective cohort study of Sickle Cell Disease (SCD) patients attending 32 treatment centers across Italy. The aim of this study will be to report the Italian experience with the use of hydroxyurea in a large cohort of SCD patients and to evaluate the benefits and safety of this intervention for the prevention and management of a wide range of clinical morbidities

Conditions

Interventions

OTHER

Physician standard-of-care in SCD patients

Sponsors & Collaborators

  • Società Italiana Talassemie ed Emoglobinopatie

    lead OTHER

Principal Investigators

  • Paolo Rigano, MD · Servico Integrado de Tecnicas Endovasculares

Eligibility

Min Age
1 Year
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-11-30
Primary Completion
2016-11-30
Completion
2017-07-31

Countries

  • Italy

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02709681 on ClinicalTrials.gov